Of note, the CAR strategy combines both the advantages of an antibody-type specificity and the effector function of T-cells, thus bypassing the poor accessibility of HER2-specific antibodies and allowing a potentially broader clinical application in cancer treatment. The gene discussed is ERBB2; the disease is cancer.